LT7082-001 is an open-label, single-arm pilot study. Patients with intermediate age-related macular degeneration (AMD) wil take T7082 during 12 months , an association of 4 food supplementations .

The study objectives are to describe morphological changes and evolution of drusen in macula after a 12-month of food supplementation and to assess the safety of T7082

Inclusion Criteria:

• Informed consent signed and dated

• Age ≥ 50 years old

• At least one Eligible Eye, defined by following conditions :

  1. Far Best Corrected Visual Acuity (BCVA) ≥ 75 ETDRS letters (or ≥ 20/32 Snellen equivalent)
  2. At least one drusen with a minimal diameter of 125 µM assessed by SD-OCT / intermediate age-related macular degeneration
  3. Macula sparing
  4. Clear ocular media
  5. Adequate pupillary dilation

Exclusion Criteria:

• Presence of other macular disease such as epiretinal membrane or macular telangiectasia.
• Presence of any geographic atrophy including macular region
• Any history of retina neovascularization
• Macula or retinal diseases other than age-related macular degeneration
• A concurrent ocular pathology that may contribute to vision loss (eg, choroidal neovascularization, glaucoma, visually significant cataract, optic neuropathy, history of retinal surgery) or interfere with acquisition of high-quality images
• Ocular or periocular infections
• Presence of congenital retinal pathologies that may impact data collection
• Exudative AMD